Rediff.com« Back to articlePrint this article

Former Armstrong teammate admits positive test

November 07, 2012 11:08 IST

South African cyclist David George, a former teammate of Lance Armstrong, has tested positive for the banned drug EPO (Erythropoietin), he said on Tuesday.

The 36-year-old former Olympian returned a positive sample after an out-of-competition test conducted by the South African Institute for Drug-Free Sport (SAIDS) in August.

"On 29th August 2012, I returned an out-of-competition positive test for Erythropoietin," George said in a statement.

"I will not be asking for a B sample to be tested as I know the result will ultimately be the same."

George, who rode alongside Armstrong in the 1999 and 2000 seasons as part of the US Postal Service team, has been provisionally suspended pending an investigation by an independent tribunal.

American Armstrong was banned for life and stripped of his seven Tour de France titles last month after former team mates testified that he had been involved in what the United States Anti-Doping Agency (USADA) described as "the most sophisticated, professionalized and successful doping program the sport has ever seen".

George's statement added: "I fully understand the consequences of my admission and will bear the results of this.

"Cycling, as you know, has been a confusing space and although it has given me incredible moments it has also given me experiences that no person or young athlete should have to go through.

"I would like to apologise to my sponsors, who have given me every opportunity to chase a dream, and team mates, for whom I have the utmost respect. I will endeavour to make right where humanly possible."

The hormone EPO increases the red blood-cell count, enabling users to augment their oxygen-carrying capacity and enhance performance.

George has been suspended by his Team 360Life, while Cycling South Africa (CSA) said: "(We) respect the independence of the SAIDS process and will respect the outcome."

Source: REUTERS
© Copyright 2024 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.